+327.1%
NET vs MRNA
+29.1%
+297.9%
-45.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.0% | -2.2% | +0.3% | -1.9% |
| 7D | -7.0% | +5.5% | -12.5% | -7.1% |
| 30D | -4.8% | +158.7% | -163.5% | -8.2% |
| 3M | +3.8% | +182.1% | -178.3% | -1.2% |
| 6M | +50.0% | +151.8% | -101.8% | +43.9% |
| YTD | +41.5% | +393.6% | -352.1% | +23.3% |
| 1Y | +32.8% | +499.5% | -466.6% | +11.6% |
| All | +327.1% | +29.1% | +297.9% | +274.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling